Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Current standards for first-line metastatic hormone-sensitive prostate cancer

Paul Monk, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the treatments for patients with castration-resistant prostate cancer. These patients are resistant to androgen receptor targeting drugs and are therefore usually treated with enzalutamide and abiraterone. Nevertheless, alternative more efficacious treatments are needed. Dr Monk explains that the results from the Phase Ib/II trial (NCT03910660) evaluating BXCL701 (talabostat) in combination with pembrolizumab are eagerly awaited to see if this new agent demonstrates a significant efficacy and acceptable toxicity profile in this patient population.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.